Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era?

Summary The use of granulocyte colony-stimulating factor (G-CSF) in patients with haematological malignancies is associated with less febrile neutropenia episodes. But in the presence of COVID-19 infection, the administration of G-CSF is challenging as it may trigger a robust inflammatory reaction r...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2021-03, Vol.124 (7), p.1183-1183
Main Author: Malek, Alexandre E.
Format: Article
Language:English
Subjects:
631/67/71
692/420
Biomedical and Life Sciences
Biomedicine
Cancer Research
Colony-stimulating factor
Comment
Coronaviruses
COVID-19
COVID-19 - complications
COVID-19 - epidemiology
COVID-19 - virology
Cytokine Release Syndrome - chemically induced
Cytokine storm
Cytokines
Drug Resistance
Epidemiology
Granulocyte colony-stimulating factor
Granulocyte Colony-Stimulating Factor - administration & dosage
Granulocyte Colony-Stimulating Factor - adverse effects
Hematologic Neoplasms - complications
Hematologic Neoplasms - therapy
Hematopoietic Stem Cell Transplantation
Humans
Inflammation
Leukocytes (granulocytic)
Molecular Medicine
Neutropenia
Oncology
Prognosis
Respiratory failure
Respiratory Insufficiency - chemically induced
SARS-CoV-2 - isolation & purification
Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The use of granulocyte colony-stimulating factor (G-CSF) in patients with haematological malignancies is associated with less febrile neutropenia episodes. But in the presence of COVID-19 infection, the administration of G-CSF is challenging as it may trigger a robust inflammatory reaction resulting in cytokine storm, respiratory failure and severe outcomes.
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-020-01195-8